Various immunomodulatory treatments have been applied to women with recurrent pregnancy losses since a significant proportion of them have cellular and autoimmune abnormalities. However, immunomodulatory treatments are often considered controversial for their efficacies. Often, they are provided to unselected patients without investigating potential etiologies by healthcare providers without appropriate reproductive immunology training and qualifications. To eliminate these concerns,the American Society for Reproductive Immunology (ASRI) established the Clinical Reproductive Immunology Fellowship and has been certifying reproductive immunologists. The approach to RPL from a reproductive immunology perspective requires a detailed understanding of underlying immunopathology, advanced knowledge of clinical and basic science and translational research, and the capability to evaluate the available evidence. The immunotherapy guideline development group, composed of clinical reproductive immunology fellows, ASRI, reviewed the currently available data and developed the clinical guidelines for immunotherapy.

由于反复流产的女性中有相当一部分存在细胞和自身免疫异常，因此各种免疫调节疗法已被应用于此类女性。然而，免疫调节疗法的疗效往往存在争议。通常情况下，未经适当生殖免疫学培训和资质认证的医疗保健提供者会向未经过筛选的患者提供这些疗法，且未对潜在病因进行调查。为消除这些担忧，美国生殖免疫学会（ASRI）设立了临床生殖免疫学研究员职位，并一直在认证生殖免疫学家。从生殖免疫学的角度来看待反复流产，需要对潜在的免疫病理学有详细的了解，具备临床和基础科学以及转化研究的高级知识，并能够评估现有证据。由临床生殖免疫学研究员和 ASRI 组成的免疫治疗指南制定小组审查了目前可用的数据，并制定了免疫治疗的临床指南。